Agent Capital
Andrea Heslin Smiley serves as the President and CEO of VMS BioMarketing since 2008 and holds a position in Business Development at the same company. In addition, Andrea is on the Board of Directors at atai Life Sciences and Rockwell Medical, Inc., and has provided advisory services at Agent Capital. Prior board memberships include Assertio Corporation and Zyla Life Sciences. Prior to these roles, Andrea accumulated extensive experience at Eli Lilly and Company, where key positions included Vice President of the Osteoporosis Business Unit and leadership roles in Growth Hormone, Endocrine, and Diabetes units, as well as corporate strategy and business development. Early career roles include healthcare consulting at Putnam Associates, business development analysis at Harvard University, and a combination of financial analysis and sales representation at Eli Lilly. Andrea holds a Bachelor of Arts degree in Economics from DePauw University.
This person is not in any teams
This person is not in any offices
Agent Capital
Agent Capital is a healthcare investment firm focused on novel technologies and therapeutics that address unmet patient need. Their investment areas of focus are new products and technologies for oncology, immunology, neurology and rare disease indications. They make direct equity investments across all stages of development and types of financing rounds.